In an effort to promote greater understanding of Temporomandibular Disorders (TMD) and to develop safe and effective evidence-based diagnostics and treatments. The TMJ Association promotes and encourages basic and clinical research on TMD. We invite you to view a listing of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.
The purpose of this Notice is to inform potential applicants concerned with the NIH Blueprint Neurotherapeutics Network (BPN) Funding Opportunity Announcements about the areas of special interest. The National Institute of Neurological Disorders and Stroke (NINDS) is interested in receiving applications directed at identifying and developing the new small molecule pain therapies. The National Institute on Drug Abuse (NIDA) is specifically interested in receiving the highly innovative applications, entering the BPN in the discovery phase only, directed at identifying new small molecules devoid of addictive properties for the treatment of pain.Additionally, the BPN will hold an informational webinar on the program for potential applicants. The webinar is recommended for investigators who have small molecule validated hit compounds and the disease biology assays to drive lead optimization who are interested in learning about the BPN and it virtual pharma model that brings NIH investigators together with NIH expertise, seasoned industry consultants and BPN's contract resources.
The purpose of this funding opportunity announcement (FOA) is to encourage research on mechanisms underlying the manifestations of sex-based differences in Dental, Oral, and Craniofacial (DOC)-related diseases and conditions. Specifically, this initiative encourages studies aimed at understanding immune reactivity, genetic variation, environmental triggers, aging, and hormonal changes as they affect sex-based differences in DOC-related diseases and conditions including, but not limited to, Sjögren’s Syndrome (SS), orofacial pain, temporomandibular joint (TMJ) disorder (TMD), salivary gland tumors, and human papillomavirus (HPV)-associated oropharyngeal cancers.
The FaceBase Consortium is developing a variety of comprehensive datasets on craniofacial development that are available to the wider scientific community at www.facebase.org. This funding opportunity announcement (FOA) will support meritorious research projects that conduct secondary data analyses of these FaceBase datasets relevant to craniofacial development, human craniofacial conditions or traits, and animal models of those craniofacial conditions. Informatics projects that integrate data from multiple FaceBase datasets are especially encouraged.
This Funding Opportunity Announcement encourages research to address gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise dental treatment guidelines tailored to patient needs. It is expected that research applications will propose studies utilizing established cohorts of individuals with the disease of interest.
The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms.
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality. Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch. Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation. This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs). The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities. Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the parent R01 FOA, PA-13-302.
The OPPERA study has demonstrated that pelvic pain is moderately associated with TMD. Given this relationship we are publicizing this research opportunity.
The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), invites research grant applications to conduct fundamental basic and translational research focused on urologic chronic pelvic pain syndrome.
The NIDDK has allocated up to $2 million to solicit basic and translational studies from investigators NEW to the MAPP Network that will be conducted in collaboration with the existing MAPP Network and in support of the Network's goals of informing future clinical investigations and ultimately improving clinical management of urologic chronic pelvic pain syndrome patients.
Applications may request up to $500,000 and will be supported through sub-contracts to the MAPP Network's Data Coordination Core (DCC) at the University of Pennsylvania. The application receipt date is June 15, 2015. For additional information see the MAPP Network website (http://www.mappnetwork.org/)
The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
NIDCR is interested in neurotherapeutics development for painful disorders of the orofacial region including temporomandibular joint disorder, trigeminal neuropathies, burning mouth syndrome, and other conditions. Recent advances in genomics and phenotyping of subjects with orofacial pain conditions have expanded the scope of potential targets to treat these conditions. Receptor systems, ion channels, and pro- and anti-inflammatory molecules have been implicated in chronic pain. NIDCR is interested in supporting research that will lead to highly efficacious and specific pharmacological treatments of subjects with orofacial pain disorders.
Investigators are encouraged to contact NIDCR program staff to discuss potential research projects prior to application submission to determine alignment of the planned studies with priorities of the Institute mission and strategic plan.
The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches.
To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in receiving applications directed at identifying and developing the new small molecule pain therapies. The National Institute on Drug Abuse (NIDA) is specifically interested in receiving the highly innovative applications, entering the BPN in the discovery phase only, directed at identifying new small molecules devoid of addictive properties for the treatment of pain.
Additionally, the BPN will hold an informational webinar on the program for potential applicants. The webinar is recommended for investigators who have small molecule validated hit compounds and the disease biology assays to drive lead optimization who are interested in learning about the BPN and it virtual pharma model that brings NIH investigators together with NIH expertise, seasoned industry consultants and BPN's contract resources.
This webinar is optional and not required for submission of applications.
Informational Webinar on the Blueprint Neurotherapeutic Network
January 3, 2018 3:30 p.m.- 4:30 Eastern Time
Please visit the following link to register for the webinar:
Link to webinar
A registration button is available at the bottom of the page.
The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations.
The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at http://www.biomarkersconsortium.org. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.
The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.
Information about the Foundation for NIH is available at http://www.fnih.org.